Gilead Sciences Inc. — whose HIV-fighting drugs have helped to nearly triple the lives of people with the HIV virus and reduce the number of pills patients pop from 25 to one — expects this fall to ask government regulators to approve its final chronic HIV treatment.
But that's not the end of the Foster City-based company's journey with HIV patients, the company said. Instead, it will focus on drugs that act longer and, potentially, purge the AIDS virus.
Gilead (NASDAQ: GILD), which developed…
Gilead Sciences Inc. — whose HIV-fighting drugs have helped to nearly triple the lives of people with the HIV virus and reduce the number of pills patients pop from 25 to one — expects this fall to ask government regulators to approve its final chronic HIV treatment.
But that's not the end of the Foster City-based company's journey with HIV patients, the company said. Instead, it will focus on drugs that act longer and, potentially, purge the AIDS virus.
Gilead (NASDAQ: GILD), which developed…